Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

Market Cap	13.60B +18.4%
Revenue (ttm)	2.98B +6.2%
Net Income	937.93M -10.8%
EPS	2.91 -10.7%
Shares Out	322.32M
PE Ratio	14.50
Forward PE	n/a
Dividend	1.76 (4.19%)
Ex-Dividend Date	n/a

Volume	4,221,760
Average Volume	3,923,952
Open	42.45
Previous Close	41.92
Day's Range	41.92 - 42.70
52-Week Range	34.60 - 57.98
Beta	0.38
RSI	51.39
Earnings Date	Mar 13, 2026

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-releas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 671
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600211

Financial Performance

In 2025, SHA:600211's revenue was 2.98 billion, an increase of 6.23% compared to the previous year's 2.81 billion. Earnings were 937.93 million, a decrease of -10.78%.